Esophageal Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Esophageal Cancer – Pipeline Review, H2 2017’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer

The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects

The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Esophageal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adaptimmune Therapeutics Plc

ADC Therapeutics Sarl

Aduro BioTech Inc

Advenchen Laboratories LLC

Almac Discovery Ltd

Ambrx Inc

Amgen Inc

Aprea AB

ArQule Inc

Array BioPharma Inc

Aslan Pharmaceuticals Pte Ltd

Bayer AG

BeiGene Ltd

BioStar Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cascadian Therapeutics Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Clovis Oncology Inc

Cyclacel Pharmaceuticals Inc

DAE HWA Pharmaceutical Co Ltd

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

Genmab A/S

GlaxoSmithKline Plc

Glycotope GmbH

Hanmi Pharmaceuticals Co Ltd

Hutchison MediPharma Ltd

Ignyta Inc

Immunocore Ltd

ImmunoFrontier Inc

Immunomedics Inc

Incyte Corp

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Leap Therapeutics Inc

Madrigal Pharmaceuticals Inc.

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merrimack Pharmaceuticals Inc

Novartis AG

Omeros Corp

Omnitura Therapeutics Inc

Oncolys BioPharma Inc

Ono Pharmaceutical Co Ltd

Puma Biotechnology Inc

Rhizen Pharmaceuticals SA

Shionogi & Co Ltd

Spectrum Pharmaceuticals Inc

Steba Biotech SA

Stelic Institute & Co Inc

Supratek Pharma Inc

Symphogen A/S

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Takara Bio Inc

Transgene Biotek Ltd

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Esophageal Cancer - Overview 6

Esophageal Cancer - Therapeutics Development 7

Esophageal Cancer - Therapeutics Assessment 21

Esophageal Cancer - Companies Involved in Therapeutics Development 35

Esophageal Cancer - Drug Profiles 64

Esophageal Cancer - Dormant Projects 561

Esophageal Cancer - Discontinued Products 565

Esophageal Cancer - Product Development Milestones 566

Appendix 579

List of Tables

List of Tables

Number of Products under Development for Esophageal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Esophageal Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Esophageal Cancer – Pipeline by ADC Therapeutics Sarl, H2 2017

Esophageal Cancer – Pipeline by Aduro BioTech Inc, H2 2017

Esophageal Cancer – Pipeline by Advenchen Laboratories LLC, H2 2017

Esophageal Cancer – Pipeline by Almac Discovery Ltd, H2 2017

Esophageal Cancer – Pipeline by Ambrx Inc, H2 2017

Esophageal Cancer – Pipeline by Amgen Inc, H2 2017

Esophageal Cancer – Pipeline by Aprea AB, H2 2017

Esophageal Cancer – Pipeline by ArQule Inc, H2 2017

Esophageal Cancer – Pipeline by Array BioPharma Inc, H2 2017

Esophageal Cancer – Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017

Esophageal Cancer – Pipeline by Bayer AG, H2 2017

Esophageal Cancer – Pipeline by BeiGene Ltd, H2 2017

Esophageal Cancer – Pipeline by BioStar Pharmaceuticals Inc, H2 2017

Esophageal Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Esophageal Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2017

Esophageal Cancer – Pipeline by Cascadian Therapeutics Inc, H2 2017

Esophageal Cancer – Pipeline by CBT Pharmaceuticals Inc, H2 2017

Esophageal Cancer – Pipeline by Celgene Corp, H2 2017

Esophageal Cancer – Pipeline by Celldex Therapeutics Inc, H2 2017

Esophageal Cancer – Pipeline by Cellectar Biosciences Inc, H2 2017

Esophageal Cancer – Pipeline by Clovis Oncology Inc, H2 2017

Esophageal Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017

Esophageal Cancer – Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Eli Lilly and Co, H2 2017

Esophageal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Esophageal Cancer – Pipeline by Genmab A/S, H2 2017

Esophageal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2017

Esophageal Cancer – Pipeline by Glycotope GmbH, H2 2017

Esophageal Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Hutchison MediPharma Ltd, H2 2017

Esophageal Cancer – Pipeline by Ignyta Inc, H2 2017

Esophageal Cancer – Pipeline by Immunocore Ltd, H2 2017

Esophageal Cancer – Pipeline by ImmunoFrontier Inc, H2 2017

Esophageal Cancer – Pipeline by Immunomedics Inc, H2 2017

Esophageal Cancer – Pipeline by Incyte Corp, H2 2017

Esophageal Cancer – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Johnson & Johnson, H2 2017

Esophageal Cancer – Pipeline by Leap Therapeutics Inc, H2 2017

Esophageal Cancer – Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Esophageal Cancer – Pipeline by MaxiVAX SA, H2 2017

Esophageal Cancer – Pipeline by Mebiopharm Co Ltd, H2 2017

Esophageal Cancer – Pipeline by MedImmune LLC, H2 2017

Esophageal Cancer – Pipeline by Merck & Co Inc, H2 2017

Esophageal Cancer – Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Esophageal Cancer – Pipeline by Novartis AG, H2 2017

Esophageal Cancer – Pipeline by Omeros Corp, H2 2017

Esophageal Cancer – Pipeline by Omnitura Therapeutics Inc, H2 2017

Esophageal Cancer – Pipeline by Oncolys BioPharma Inc, H2 2017

Esophageal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Puma Biotechnology Inc, H2 2017

Esophageal Cancer – Pipeline by Rhizen Pharmaceuticals SA, H2 2017

Esophageal Cancer – Pipeline by Shionogi & Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Spectrum Pharmaceuticals Inc, H2 2017

Esophageal Cancer – Pipeline by Steba Biotech SA, H2 2017

Esophageal Cancer – Pipeline by Stelic Institute & Co Inc, H2 2017

Esophageal Cancer – Pipeline by Supratek Pharma Inc, H2 2017

Esophageal Cancer – Pipeline by Symphogen A/S, H2 2017

Esophageal Cancer – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017

Esophageal Cancer – Pipeline by Taiwan Liposome Company Ltd, H2 2017

Esophageal Cancer – Pipeline by Takara Bio Inc, H2 2017

Esophageal Cancer – Pipeline by Transgene Biotek Ltd, H2 2017

Esophageal Cancer – Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Esophageal Cancer – Dormant Projects, H2 2017

Esophageal Cancer – Dormant Projects, H2 2017 (Contd..1), H2 2017

Esophageal Cancer – Dormant Projects, H2 2017 (Contd..2), H2 2017

Esophageal Cancer – Dormant Projects, H2 2017 (Contd..3), H2 2017

Esophageal Cancer – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Esophageal Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports